AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Pomerantz LLP Investigating TechTarget Securities Fraud Claims
ByAinvest
Tuesday, Apr 29, 2025 10:47 am ET1min read
Pomerantz LLP is investigating claims of securities fraud against TechTarget, Inc. (NASDAQ: TTGT) and its officers and directors. The investigation concerns TechTarget's failure to timely file its Annual Report on Form 10-K for the year ended December 31, 2024. As a result, TechTarget's stock price fell 12.75% to $7.12 per share on April 21, 2025. Investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980 for further information.
Pomerantz LLP, a prominent law firm specializing in corporate and securities litigation, has initiated an investigation into potential claims of securities fraud against TechTarget, Inc. (NASDAQ: TTGT) and its officers and directors. The investigation centers on TechTarget's failure to timely file its Annual Report on Form 10-K for the year ended December 31, 2024.On March 31, 2025, TechTarget disclosed that it would be unable to meet the deadline for filing its 2024 Annual Report. The company attributed this delay to the need for further evaluation of technical accounting matters related to its combination with the "Informa Tech Digital Businesses" [2]. Additionally, TechTarget revealed that it expects to record a pre-tax non-cash goodwill impairment charge related to the business in the range of approximately $70 million to $110 million for the 2024 fiscal year.
Following these disclosures, TechTarget's stock price experienced a significant decline. On April 1, 2025, the stock closed at $12.76 per share, a 12.75% decrease from its previous closing price of $14.81 per share on March 31, 2025 [2].
Investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980 for further information about the investigation.
References:
[1] https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-adverum-biotechnologies-inc---advm-302440201.html
[2] https://www.tradingview.com/news/reuters.com,2025-04-29:newsml_GNX7KgHXc:0-bragar-eagel-squire-p-c-is-investigating-techtarget-and-aldeyra-and-encourages-investors-to-contact-the-firm/
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet